+1 Billion people have migraine
In spite of the fact that over one billion people have migraine, there still is no objective test for it. This unmet need creates a major opportunity for early investors in the commercialization of a test.
What We Do
Innovation means hope. From our inception, we have kept the focus on innovative discovery as we believe this is the proper foundation for our company.
Our Vision
To leverage our understanding of the electrical activity of the brain, and translate it into a full range of patient diagnostic and monitoring services, starting with migraine.
Our Company Tagline
This is “Hope through discovery” to reflect the company’s belief that innovation is the cornerstone of fulfilling out company mission.
Our mission is to provide the practitioner the tools they need to improve the diagnostics, monitoring and treatment of headache related neurogenic and neurodegenerative disorders and diseases.
Limitations in current diagnostic techniques result in serious problems in underdiagnosis, overdiagnosis and inadequate monitoring which leads to frequent undertreatment in some cases and overtreatment in others for many of the 1 billion migraine sufferers in the world.
World Health Organization Statement
A key study of headache epidemiology, Atlas of Headache Disorders and Resources in the World 2011, was conducted by the WHO and published in 2011.
The study identified what it called its “Key messages” which included the following:
Headache disorders are ubiquitous, prevalent and disabling. Yet they are under-recognized, under diagnosed and under-treated worldwide.
A minority of people with headache disorders are professionally diagnosed.
Illness that could be relieved is not, and burdens, both individual and societal, persist unnecessarily and financial costs to society through lost productivity are enormous.
World’s first brain movie of a migraine headache in progress.
This brain movie of a real person with a migraine attack that is underway was created by team members Garingo and Doidge.The images were made by our team using a technology called “source localization”. While it is not currently being used by our company for the diagnosis of migraine, it is still useful to illustrate the rapidity and complexity of the types of brain signals that we are deciphering. The lines you see are called “current density vectors”. They represent the mathematically inferred locations of the generators of delta (slowest), theta (moderately slow) and alpha waves which are somewhat faster. This movie is slowed down 30 fold. Machine learning technologies are needed to make sense of the waveforms seen on EEG.
47 million in the US and 80 million in Western Europe.
Age-standardized prevalence of migraine per 100,000 population by location for both sexes, 2016 GBD 2016 Headache Collaborators, Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17: 954-976. doi:10.1016/S1474-4422(18)30322-3 and Figure 1
Fundamentals of our business: why we are different.
We are a new type of health business which uses a cutting edge technology that the FDA calls “Software as a Medical Device” or SaMD. Historically, the great fortunes in health care were made by drug companies and medical device companies. We are neither. We are what the FDA calls a “Software as a Medical Device Company.
Affinity with Big Pharma
• We believe our company has a natural affinity to work with big pharma because when a patient gets a clear diagnosis, they are more inclined to take one of the many available drug treatments. This is sometimes referred to as “companion diagnostic”.
• Future studies could lead to improved efficacy in selection of medications.
• Pharma needs biomarkers to verify if a drug is working and to reduce very expensive drug development costs.
• The Company’s newly discovered biomarkers come from BETWEEN attacks, suggesting they may be fundamental to the disease.
• We hope one day to work with forward looking drug companies aiming to try to create a whole new generation of migraine treatment drugs. There is an urgent need for small pilot studies of electrical drugs. Presently several of the FDA approved drugs for migraine are electrical including Topiramate.
• We believe that with the help of HSI’s biomarkers it may be possible to surpass it and other existing electrical drugs.
Recent Events
We are a new type of health business which uses a cutting edge technology that the FDA calls “Software as a Medical Device” or SaMD. Historically, the great fortunes in health care were made by drug companies and medical device companies. We are neither. We are what the FDA calls a “Software as a Medical Device Company.
Meet Our Team
We take pride in our dedicated and diverse team. Each member brings a unique set of skills, expertise, and a shared passion for our mission. Together, we work tirelessly to deliver the best solutions and services to our valued clients. Get to know the faces behind our success:
DR. MARK DOIDGE MD
President
Dr. Gaurav Anand MD
Chief Operating Officer
Mario Garingo
Chief Technical Officer
